A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a combination of study drugs called
selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone. This study tests
different doses of the study drug, selinexor to see which dose is safer in people. Depending
on which group (dose level) you are in, the dose of selinexor will vary, but the ixazomib and
dexamethasone doses will be the same among the groups.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Karyopharm Therapeutics Inc Karyopharm Therapeutics, Inc Millennium Pharmaceuticals, Inc.